Skip to main content

Clinical trial ANDROMEDA

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Organ Amyloidose
Trial status Trial open for recruitment
Trial type
Interventionnal with IMP
Phase Trial phase 3
Academic trial Non
Sponsor Janssen
EudraCT Identifier 2016-001737-27
Inclusion criteria Histopathological diagnosis of amyloidosis based on detection by IHC and polarizing light microscopy of green bi-refringent material in congo red-stained tissue specimens (in an organ other than bone marrow) or characteristic electron microscopy appearanc
Last update